The Sanofi-backed vaccine developer has filed to float on the Nasdaq Global Select Market and set a placeholder target of $100m.

GV contributed to the precision oncology platform developer's series A round, which will fund technology development and clinical studies.

Novo and Sanofi Ventures both participated in a series A round for the neurodegenrative disease drug developer, which is led by EIRs at Novo Seeds.

The musculoskeletal healthcare provider has added cash from Intermountain Healthcare, Ascension Ventures and Echo Health Ventures to a round now surpassing $50m.

VIB and V-Bio Ventures have both participated in a series A round for Muna Therapeutics, the result of a merger of two recent spinouts.

University of Washington spinout Icosavax has filed for an initial public offering on the Nasdaq Global Select Market, with financial terms yet to be set.

Drug discovery technology developer Standigm added $10m to the cash it raised from SK Chemicals last week while Six FinTech Ventures helped fintech software provider Toqio secure $9.4m.

Swisscom and Hitachi-backed genomic data technology provider Sophia has filed to go public following some $250m in venture funding.

Mitsui and Nan Fung could exit the rare disease drug developer, which is set to float on the Nasdaq Global Select Market having set a $100m placeholder target.

The venture firm is working on a new vehicle which could be larger in size than its Sega Sammy and Septeni-backed second fund.